guest ::
| Home > Publications Database > The economic burden of subjective cognitive decline, mild cognitive impairment and Alzheimer's dementia: excess costs and associated clinical and risk factors. |
| Home > Publications Database > The economic burden of subjective cognitive decline, mild cognitive impairment and Alzheimer's dementia: excess costs and associated clinical and risk factors. |
| Journal Article | DZNE-2025-01034 |
; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ;
2025
BioMed Central
London
This record in other databases: 
Please use a persistent id in citations: doi:10.1186/s13195-025-01785-9
Abstract: With the availability of first disease-modifying treatments, evidence on costs across the entire Alzheimer's Continuum, especially for early disease stages, becomes increasingly important to inform healthcare planning, resource allocation, and policy decisions. This study assessed costs and cost-associated factors in patients with subjective cognitive decline (SCD), mild cognitive impairment (MCI) and Alzheimer's Disease (AD) dementia compared to healthy controls.The German DELCODE cohort study assessed clinical data, healthcare resource use, and informal care provision. Costs were calculated from payer and societal perspectives using standardized unit costs, and multivariate regression analyses identified cost-associated factors.From a payer perspective, costs were elevated by 26% for SCD (adjusted mean 5,976€ [95%CI 4,598-7,355€]), 85% for MCI (8,795€ [6,200-11,391€]) and 36% for AD (6,454€ [2,796-10,111€]) compared to controls (4,754€ [3,586-5,922€]). Societal costs were elevated by 52% for SCD (adjusted mean 8,377€ [95%CI 6,009-10,746€]), 170% for MCI (14,886€ [9,524-20,248€]) and 307% for AD (22,481€ [9,994-34,969€]) compared to controls (5,522€ [3,814-7,230€]). APOE e4 negative patients showed higher costs compared to APOE e4 positive patients. Hypertension was associated with higher costs.Healthcare costs are already elevated in early subjective and objective cognitive impairment, driven by formal and informal care. The study emphasizes the importance of early interventions to reduce the economic burden and delay progression.
Keyword(s): Humans (MeSH) ; Cognitive Dysfunction: economics (MeSH) ; Cognitive Dysfunction: epidemiology (MeSH) ; Cognitive Dysfunction: therapy (MeSH) ; Male (MeSH) ; Female (MeSH) ; Alzheimer Disease: economics (MeSH) ; Alzheimer Disease: epidemiology (MeSH) ; Alzheimer Disease: therapy (MeSH) ; Aged (MeSH) ; Cost of Illness (MeSH) ; Risk Factors (MeSH) ; Health Care Costs (MeSH) ; Aged, 80 and over (MeSH) ; Germany: epidemiology (MeSH) ; Cohort Studies (MeSH) ; Middle Aged (MeSH) ; Alzheimer’s disease ; Apolipoprotein E ; Cognition ; Cost ; Dementia ; Economics ; Mild cognitive impairment ; Subjective cognitive decline ; Utilization
; 
; 
; 
; Article Processing Charges ; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; DOAJ Seal ; Ebsco Academic Search ; Essential Science Indicators ; Fees ; IF >= 5 ; JCR ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection
PDF
PDF (PDFA)